Related Experiment Videos
A preclinical model for experimental chemotherapy of human head and neck cancer
K Sommer1, S O Peters, I H Robins
1Department of Otorhinolaryngology, University Hospital Lubeck, D-23538 Lubeck, Germany. konrad.sommer@medinf.mu-luebeck.de
Abstract:
We developed a mouse model in a representative human derived head and neck cancer cell line for preclinical studies to evaluate antitumor response, tumor-free survival and host toxicity of alkylating agents, antimetabolites, platinum analogs and taxanes alone or in combination. Ninety athymic NMRI mice were inoculated with human derived oral squamous cell carcinoma cells growing on the hind paw to an average volume of 180 +/- 80 mm3. Animals were stratified according to tumor volume into 10 groups (n=6-10) and treated with ifosfamide (65 mg/kg b.w.), docetaxel (24 mg/kg b.w.), cisplatin (2 mg/kg b.w.), carboplatin (6 or 10 mg/kg b.w.), methotrexate (1 mg/kg b.w.), and fluorouracil (15 mg/kg b.w.) intravenously in single agent or combination (ifosfamide plus docetaxel or ifosfamide plus carboplatin) treatment schedules or controls. Tumor volume was measured 3 times per week for 60 days. The average tumor volume, the overall survival time and the response rates (CR, PR) of the treated animals were compared with the data obtained from untreated controls and statistically evaluated. Untreated tumors showed rapid and exponential tumor growth. Single agent therapies with ifosfamide, cisplatinum, and docetaxel lead to significant tumor regression and improved overall survival. Low dose carboplatin monotherapy induced significant tumor growth delay, but not significant tumor regression. Most impressive tumor-free survival was achieved by combination treatment with ifosfamide and docetaxel. This preclinical study demonstrates an animal model capable of differentiating various chemotherapy regimens.
Insights
A new mouse model effectively evaluated chemotherapy for head and neck cancer. Combination therapy with ifosfamide and docetaxel demonstrated the best tumor-free survival in this preclinical study.
Area of Science:
- Oncology
- Preclinical Research
- Pharmacology
Background:
- Head and neck cancers present significant treatment challenges.
- Evaluating novel chemotherapy regimens requires robust preclinical models.
- Understanding drug efficacy and toxicity is crucial for clinical translation.
Purpose of the Study:
- To develop and validate a mouse model for assessing chemotherapy in head and neck cancer.
- To compare the antitumor response, survival, and toxicity of various chemotherapeutic agents.
- To identify optimal single-agent and combination chemotherapy strategies.
Main Methods:
- A human oral squamous cell carcinoma cell line was used to establish tumors in athymic NMRI mice.
- Mice with established tumors were treated with single agents (ifosfamide, docetaxel, cisplatin, carboplatin, methotrexate, fluorouracil) or combinations.
- Tumor volume, survival, and response rates (complete and partial remission) were monitored and statistically analyzed over 60 days.
Main Results:
- Untreated tumors exhibited rapid exponential growth.
- Single-agent ifosfamide, cisplatin, and docetaxel significantly reduced tumor volume and improved survival.
- Combination therapy with ifosfamide and docetaxel yielded the most significant tumor-free survival.
- Low-dose carboplatin showed tumor growth delay but not significant regression.
Conclusions:
- The developed mouse model is effective for differentiating chemotherapy regimens in head and neck cancer.
- Ifosfamide and docetaxel combination therapy shows promise for maximizing tumor-free survival.
- This model provides a valuable platform for preclinical evaluation of cancer therapeutics.